NDA 017531 · King Pharms LLC
Tigan
Trimethobenzamide Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Mar 13, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1974
Jul 12, 1974
Approved uses
2
Original approval plus efficacy supplements
Registered trials
5
0 Phase 3, 1 recruiting
FAERS reports
1,417
494 serious, 61 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 13, 2001 Supplement 10 · Efficacy LetterLabelReview
- Jul 12, 1974 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- TIGAN · TRIMETHOBENZAMIDE HYDROCHLORIDE 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Trimethobenzamide" as an intervention, any sponsor and status, largest first.
- Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersPivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT07681076 · 180 participants (planned) · Start Sep 3, 2026 · Primary completion Nov 30, 2026
Drug: KarXT; Trimethobenzamide and 2 more · For: Healthy Volunteers
Sites: Los Alamitos, California; Hollywood, Florida; Atlanta, Georgia · 4 sites in all
MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsIndustry
NCT01770145 · 127 participants · Start Dec 2012 · Primary completion Apr 2014
Drug: APOKYN; L-dopa and 1 more · For: Parkinson's Disease; Motor Symptoms; Akinesia and 2 more
Sites: Los Angeles, California; Reseda, California; Washington D.C., District of Columbia · 12 sites in all
- Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and TreatmentPivotal-lookingCompleted
IpsenIndustry
NCT00489255 · 117 participants · Start May 2007 · Primary completion Dec 2011
Drug: Tigan®; Placebo · For: Parkinson's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; La Jolla, California · 27 sites in all
PfizerPfizer (PFE)
NCT02373072 · 18 participants · Start Mar 2015 · Primary completion Feb 2016
Drug: PF-06649751; Trimethobenzamide Hydrochloride and 1 more · For: Idiopathic Parkinson Disease
Sites: Long Beach, California; Hallandale, Florida; Atlanta, Georgia · 8 sites in all
PfizerPfizer (PFE)
NCT02262767 · 9 participants · Start Nov 2014 · Primary completion Dec 2014
Drug: PF-06649751; Trimethobenzamide Hydrochloride · For: Healthy
Sites: Brussels, Belgium · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea332
- somnolence228
- dizziness166
- vomiting132
- yawning121
- drug ineffective102
- blood pressure decreased101
- fatigue93
- fall78
- blood pressure increased68
- feeling abnormal66
- drug hypersensitivity62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 24 |
| 2005 | 28 |
| 2006 | 30 |
| 2007 | 44 |
| 2008 | 30 |
| 2009 | 27 |
| 2010 | 32 |
| 2011 | 41 |
| 2012 | 51 |
| 2013 | 34 |
| 2014 | 22 |
| 2015 | 45 |
| 2016 | 81 |
| 2017 | 161 |
| 2018 | 214 |
| 2019 | 183 |
| 2020 | 181 |
| 2021 | 127 |
| 2022 | 31 |
| 2023 | 12 |
| 2024 | 11 |
| 2025 | 1 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tigan* (Trimethobenzamide HCl)
2024 spending
$196K
Beneficiaries
173
291 claims
Per beneficiary
$1,132
$25.99 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $193,861 |
| 2021 | $212,624 |
| 2022 | $240,518 |
| 2023 | $161,926 |
| 2024 | $195,915 |
Part B: Tigan (Trimethobenzamide HCL) · HCPCS J3250
2024 spending
$29K
Beneficiaries
339
649 claims
Per beneficiary
$84
2024 ASP limit $49.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $92,686 |
| 2021 | $104,376 |
| 2022 | $90,028 |
| 2023 | $58,558 |
| 2024 | $28,584 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A controlled double-blind study of trimethobenzamide, prochlorperazine, and placebo.
Bardfeld PA · JAMA 1966 · Clinical Trial, Randomized Controlled Trial
- Evaluation of trimethobenzamide hydrochloride (Tigan) suppositories for treatment of nausea and vomiting in children.
Ginsburg CM, Clahsen J · J Pediatr 1980 · Clinical Trial, Comparative Study
- Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
Dewey RB, Maraganore DM, Ahlskog JE, et al. · Clin Neuropharmacol 1996 · Clinical Trial, Controlled Clinical Trial
- Trimethobenzamide as an antiemetic in surgery for detached retina.
Snow JC · Am J Ophthalmol 1967 · Clinical Trial, Controlled Clinical Trial
- Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA, Olanow CW, Dzyngel B, et al. · Mov Disord 2016 · Clinical Trial, Phase II, Multicenter Study
- An evaluation of the teratogenicity of certain antinauseant drugs.
Milkovich L, van den Berg BJ · Am J Obstet Gynecol 1976 · Clinical Trial, Comparative Study
Sponsor: King Pharms LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.